Evolvere BioSciences GTM brain

Evolvere BioSciences develops precision antibiotic candidates and AI models aimed at antimicrobial resistance, with pharmaceutical partners a potential audience.

category

Antibiotic discovery biotechnology

market profile

  • text: Antibiotic resistance and difficult reimbursement economics create demand for differentiated antibacterial development approaches.
  • text: Evolvere has described both drug development and licensing AI models to other companies; public evidence does not establish clinical efficacy.

personas

  • title: Infectious disease pharmaceutical business development lead
    pains:
    • Finding differentiated antibacterial assets with convincing translational data
    • Assessing development economics and durability before a license deal
  • title: Biotech computational biology research leader
    pains:
    • Needs evidence that computational hypotheses translate to experimental outcomes
    • Limited internal resources for biological model development
  • title: Antimicrobial resistance translational funder
    pains:
    • Must choose which early programs can advance toward useful antibiotics
    • Needs milestones and independent evidence for allocation decisions

icp

  • text: Potential collaborators include pharmaceutical or biotech organizations with antibacterial discovery and licensing capabilities; customer relationships are not confirmed.
  • text: AMR-focused translational funders and academic research groups are plausible partners for early validation; no size threshold is supported.

objections

  • objection: Is there evidence the candidates work in patients?
    response: Request current preclinical and clinical development data; the sources reviewed do not establish clinical outcomes.
  • objection: How durable is the activity against resistance?
    response: Assess the experimental resistance and durability data for each candidate rather than assuming resistance is impossible.
  • objection: What can be licensed and under what terms?
    response: Ask the team to clarify available model and asset rights, validation and commercial terms.

competitors

  • name: Phare Bio
    website: https://www.pharebio.org/
    why: Uses AI to discover new antibiotic classes, with a different social venture model.
  • name: Locus Biosciences
    website: https://en.wikipedia.org/wiki/Locus_Biosciences
    why: Develops targeted antibacterial therapeutics using a different phage approach.

influencers

  • name: Piotr Jedryszek
    url: https://enspire.ox.ac.uk/article/piotr-jedryszek-co-founder-of-evolvere-biosciences
    why: Co-founder describes the company's antibiotic discovery mission.
  • name: Weronika Slesak
    url: https://www.bioescalator.ox.ac.uk/news-and-events/news/introducing-evolvere-biosciences
    why: Co-founder discusses antibiotic resistance and development economics.

keywords

  • antimicrobial resistance drug discovery
  • AI antibiotic discovery
  • precision antibiotics biotech
  • antibiotic licensing opportunities
  • antibacterial drug discovery collaboration
  • protein antibiotic development

voice

  • Scientific
  • Mission-led

signals

  • text: A pharmaceutical partner is seeking external antibacterial candidates or discovery collaborations.
  • text: A funder opens a translational antimicrobial resistance program.

pricing

model: unknown

motion

unknown

channels

  • academic ecosystem
  • scientific conferences
  • YC directory

confidence

low

Founders

  • name: Adam Winnifrith
    title: Founder/CEO
    role: CEO
    bio: Evolvere (S24), CEO & Co-Founder, MBioChem Oxford, I work at the intersection of bioengineering, protein AI, and automation. E.S.B
  • name: Piotr Jedryszek
    title: Founder/CTO
    role: CTO
    bio: S24, Evolvere Biosciences, CTO and Co-founder, background in Bio and CompBio
  • name: Weronika Slesak
    title: Founder
    role: Founder
    bio: CSO at Evolvere (S24). Oxford biologist using evolution as an engineering tool.

Back to YC companies